about
Detection of human aspartyl (asparaginyl) beta-hydroxylase and homeobox B7 mRNA in brush cytology specimens from patients with bile duct cancerIL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional studyIdentification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohortIFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infectionZinc is a potent and specific inhibitor of IFN-λ3 signalling.Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent mannerDendritic cells in hepatitis C virus infection: key players in the IFNL3-genotype response.Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C.The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients.Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C.Small bowel varices secondary to chronic superior mesenteric vein thrombosis in a patient with heterozygous Factor V Leiden mutation: a case report.Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses.Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.Natural killer cell function is intact after direct exposure to infectious hepatitis C virions.Identification of CD4 T-cell epitopes in soluble liver antigen/liver pancreas autoantigen in autoimmune hepatitisThe natural killer cell response to HCV infection.Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection.Ophthalmologic complications of antiviral therapy in hepatitis C treatment.IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?Adiponectin confers protection from acute colitis and restricts a B cell immune response.FibroGENE: A gene-based model for staging liver fibrosis.IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent.IFNL3 mediates interaction between innate immune cells: Implications for hepatitis C virus pathogenesis.Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia.CC-chemokine receptor 5 (CCR5) in hepatitis C--at the crossroads of the antiviral immune response?Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5.Hepatitis C virus and the threshold of natural killer cell inhibition.The tandem-repeat polymorphism of the DC-SIGNR gene in HCV infection.Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia.A summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses.Structured treatment interruptions following immediate initiation of HAART in eight patients with acute HIV-1 seroconversion.Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection.The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C.Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.Actual endoscopic versus predicted surgical mortality for treatment of advanced mucosal neoplasia of the colon.
P50
Q28238206-DE5177B1-1A0E-466C-9575-81E5B4BD789FQ28477057-D09DFB15-3292-494B-9274-FDC7C5294BB8Q28478435-5BEAAC18-DA26-4615-85F1-7CCD894B0668Q33586624-3CD6F448-44A0-4A46-ABD2-01660F4DACD8Q33720876-BC7E0CFB-CE7D-423A-BBF7-2AE996CCF6A8Q33822643-5BCFE0CF-38C7-45FA-9D04-9045CF8EC76CQ34750577-6513CEC5-6081-4B79-850C-1878B876E830Q35197060-1F5CFED5-B934-4E81-B5C0-0F78F14D2A24Q35748913-8A9837F0-12F9-486B-8BA4-8A22B5071FF6Q35760543-711361D4-B34C-48CD-8BB2-13914E8FA6CBQ35960026-7707E7A0-2130-46D0-9048-4E1F599560CAQ35964140-57DB9763-A131-4389-A9F9-20EBAEF29805Q35964254-3AB6E7C2-F5C6-438E-BD29-FBE59E7C1A77Q36110133-EBCC1131-2852-490A-8CBB-E487C0F7D5ECQ36407362-20F205B0-0BC8-4E98-A9BE-2C2D6E2C4A15Q37185209-E033428F-C540-48F2-A58B-60B22952D02EQ37224653-890EF460-93E3-4682-B6AC-2356FE5B91F2Q37257526-76D738F6-03EB-47CC-972C-329CEA6A5421Q37279158-34791F5F-3B82-4E71-86D9-3229C8B597B3Q37285273-6EED84E9-7D9A-4595-9B7F-C2E11B467472Q37378913-1F4D8C6C-FA87-4A9E-A11B-D974594F8FDBQ37773168-60C41C45-02A6-4E8F-8E2F-AF12A8D5E90BQ38062972-68B4002C-C122-444E-AE98-19ED15D2329BQ38930497-2FE39770-0C58-4FB0-91C0-117773E3C162Q40291661-17FC0444-D2F6-4626-A7DA-F67BAE950446Q42222091-4E3F4D30-3C3F-4A92-A8E9-6DC3705C94ACQ42236944-D4469E9A-796E-4D01-8350-E57BB8C90886Q42247379-D79EAA1F-3C7D-46B4-B81D-5826EB207574Q42984759-598F6773-A5A4-489E-A646-37A8927A7CBCQ42984889-72F27D3C-3C34-4D2F-A577-2A32EBA995F6Q42988386-E78787FD-1113-4292-AEED-3126AB30BA37Q42990867-031E8712-11F1-4DEC-ADB3-606EBCC7A6FDQ42997232-3D5B7AC8-C912-48D1-9129-05FFB715C432Q43023517-7E2AD664-FA33-4AAD-A83B-E642DCCDC5B9Q43035166-FF3699DF-F637-4FC3-9FA0-D9EEB2E152B4Q44643138-742167D0-77EA-46E7-860C-BF6C3CC4D003Q44865251-A3C00D1D-4888-42EB-A945-A052E83AD4DAQ45394176-A54F2472-8C6E-4AD7-82E0-F50550B64263Q45569965-22C09679-24C8-4B58-9129-10D6024558A3Q46409520-2F1B37A4-8866-4526-9E39-35BC28BC73C1
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Golo Ahlenstiel
@ast
Golo Ahlenstiel
@en
Golo Ahlenstiel
@es
Golo Ahlenstiel
@nl
Golo Ahlenstiel
@sl
type
label
Golo Ahlenstiel
@ast
Golo Ahlenstiel
@en
Golo Ahlenstiel
@es
Golo Ahlenstiel
@nl
Golo Ahlenstiel
@sl
prefLabel
Golo Ahlenstiel
@ast
Golo Ahlenstiel
@en
Golo Ahlenstiel
@es
Golo Ahlenstiel
@nl
Golo Ahlenstiel
@sl
P106
P1153
6603158596
P31
P496
0000-0003-0026-1457